wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Rebless Nitrolong & Nitrohart Neev Quiz

Total questions: 18

Worksheet time: 18mins

Name
Class
Date
1.

NAME

4 lines
2.

HQ

4 lines
3.

REGION

4 lines
4.

Tick the correct SKUs of Rebless? More than 2 answers can be correct

a)

Rivaroxaban 10 mg

b)

Rivaroxaban 20 mg

c)

Rivaroxaban 2.5 mg

d)

Rivaroxaban 15 mg

e)

Rivaroxaban 5 mg

5.

Which of the following is a DOAC or NOAC? (More than 1 Option Correct)

a)

Dabigatran

b)

Fondaparinux

c)

Rivaroxaban

d)

Enoxaparin

e)

Apixaban

6.

Which trial of Rivaroxaban was done in CAD or PAD Patients?

a)

ROCKET-AF

b)

COMPASS Trial

c)

Einstein trial

d)

All of the above

7.

For prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients the dose of Rebless is

a)

2.5 mg BD

b)

10 mg OD

c)

15 mg BD

d)

20 mg OD

8.

Which of the following Vitamin K antagonists?

a)

Warfarin

b)

Dabigatran

c)

Enoxaparin

d)

Rivaroxaban

9.

Dose of Rivaroxaban in CAD or PAD is _______________ along with Aspirin

a)

10 mg OD

b)

15 mg BD

c)

2.5 mg BD

d)

20 mg 0D

10.

As Einstein Choice trial, Rivaroxaban reduced Recurrent VTE by ________in comparison to aspirin alone

a)

80%

b)

70%

c)

21%

11.

For treatment of pulmonary embolism (PE) what is the dose of Rivaroxaban?

a)

2.5 mg BD

b)

15 mg BD for first 21 days followed by 20 mg OD from 22nd Day of the attack

c)

20 mg BD for first 21 days followed by 20 mg OD from 22nd Day of the attack

12.

Primary efficacy outcome of Rocket-AF Trial is _______________________ which is reduced by 21% in the trial?

a)

PAD

b)

CAD

c)

Stroke and Non-CNS Embolism

13.

For prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients which strength of Rivaroxaban should be given?

a)

2.5 mg

b)

10 mg

c)

15 mg

d)

20 mg

14.

Rivaroxaban inhibits _____________________ directly?

a)

Factor X

b)

Factor Xa

c)

Factor VIIIa

d)

Prothrombin

15.

SPAF Full form

a)

Stroke Prevention in Aortic Fibrillation

b)

Stroke Prophylaxis in Artery Fibrillation

c)

Stroke Prevention in Non Valvular Atrial Fibrillation

16.

As per COMPASS trial, Rivaroxaban reduces _______________ in CAD and PAD Patients respectively.

a)

MACE

b)

MALE

c)

MACE and MALE

17.

Which of the Following the only NOAC is recommended in CAD & PAD

a)

Dabigatran 

b)

Rivaroxaban

c)

Apixaban

18.

VTE = __________+ ____________. (More than One option can be correct).

a)

PE

b)

DVT

c)

CAD

d)

PAD